Acoustic Neuroma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Acoustic neuroma, also referred to as vestibular schwannoma (VS), acoustic neurinoma, vestibular neuroma or acoustic neurofibroma, is a benign, slow-growing neoplasm arising from the sheath of the vestibular branch of the vestibulocochlear nerve. It is the most common tumor of the cerebellopontine angle and the internal auditory canal. Its symptoms include hearing loss in one ear, noise in the ear, balance problems, and vertigo. The Schwann cells that invest the vestibular portion of the vestibulocochlear nerve cause the vast majority of cases, with less than 5% arising from the cochlear nerve. With roughly equal frequency, the superior and inferior vestibular nerves appear to be the nerves of origin. It is classified into two types: sporadic acoustic neuroma, unilateral and genetic, and bilateral acoustic neuroma. Sporadic, unilateral acoustic neuromas are tumors on one side of the body in 95% of patients. They are caused by sporadic (sudden) nonhereditary mutations and occur most commonly in people between the ages of 30 and 60. On the other hand, genetic, bilateral acoustic neuromas occur in people with the genetic disorder neurofibromatosis type 2, caused by a mutation in chromosome 22 that affects the gene responsible for the production of Schwann cells. These patients frequently have other schwannoma-like tumors throughout their bodies, and their treatment may differ from unilateral tumors. The diagnosis is made with a contrast magnetic resonance imaging (MRI) or computed tomogram scan; audiometric tests are needed if the hearing impairment is present.
·
The incidence of Acoustic neuroma ranges from
1 to 2 cases per 100,000 person-years in the United States.
Thelansis’s “Acoustic Neuroma Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Acoustic
Neuroma treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Acoustic Neuroma across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Acoustic Neuroma Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment